Orphan Drugs as Strategic Assets: Lifecycle Patterns, Sales Resilience, and Market Impact
This analysis refutes the misconception of orphan drugs as niche products. Using 2025 Q1 sales data and lifecycle patterns, it demonstrates their long-term revenue resilience and strategic portfolio value.
September 12, 2025
by N55.6761
Piramal Pharma Solutions to join hands with Epirium Bio to develop and manufacture orphan drugs
The integrated programme, involving three Piramal Pharma Solutions sites, encompasses formulation development, supply of APIs and intermediates, chemistry development and manufacturing, and solid oral dosage form drug product.
August 28, 2020
by expresspharma
Orphan drugs face uphill battle in 2020: GlobalData
ODDs have been a focus of interest from the pharma industry for many years, with many companies enticed by the benefits of the enhanced regulatory processes, tax benefits and extended market exclusivity.
March 3, 2020
by expresspharma
Biologics or small molecule drugs for rare disease treatment? It is a question
To both patients and pharmaceutical practitioners, it is a question as to whether to choose biologics or small molecule drugs for rare disease treatment, since the prices are sky-high.
July 31, 2019
by PharmaSources/Miling
Little Orphan Drugs Can Lead to Big Market Rare Disease Drugs in China
In the Ice Bucket Challenge in 2014, the “amyotrophic lateral sclerosis” (ALS) patients attracted the world’s attention, and more people started to pay attention to the rare diseases.
January 22, 2018
by zhulikou431
Rare disease in EU
According to some information released by the European Medicines Agency (EMA), there are about 30 million people in Europe suffering from rare diseases, the incidence of most diseases less than one hundred thousandth.
January 9, 2018
by Zhulikou431
Rare disease in America
Rare disease is a general term for a group of diseases with a very low incidence, also known as orphan disease.
January 9, 2018
by Zhulikou431
Rhizen receives US FDA orphan drug designation
The US Food and Drug Administration (US FDA) has granted orphan drug designation for Tenalisib (RP6530) for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a BSE filing.
December 27, 2017
by expressbpd
FDA grants orphan drug status to Shire’s UC treatment SHP647
FDA has granted orphan drug designation to Shire’s investigational mucosal addressin cell adhesion molecule-1 antibody, SHP647, for the treatment of paediatric patients with moderately to severely active ulcerative colitis
December 4, 2017
by pharmaceutical-technology
GST makes ‘orphan drugs’ prices soar
MUMBAI: Prices of exorbitantly-priced life-saving medicines, used to treat rare diseases have increased by 12%, with implementation of Goods and Services Tax, resulting in skyrocketing bills and leaving many patients in the lurch.
November 27, 2017
by indiatimes
GNH India clears audit to trade orphan drugs with UK
Orphan drugs such as Ferripox, Raxone, Trientine and Mitocin will now available to the Indian population.
July 11, 2017
by expressbpd
Orphan drugs become the new favorite of pharmaceutical industry upon the huge market potential
FDA approved the marketing application of Merck Serono’s Avelumab through accelerated approval on March 23, 2017, which can be said to ignite the medical circle and again draws the public interest in words like “orphan drug” and “rare disease”.
April 7, 2017
by en-cphi.cn